Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bull Cancer ; 106(10): 847-859, 2019 Oct.
Article in French | MEDLINE | ID: mdl-31521255

ABSTRACT

INTRODUCTION: The Cancer Observatory, from the OMEDITs (Observatory for Medicines and Medical Devices and Treatment Innovations) of Bretagne and Pays de la Loire areas has conducted a survey aiming to know and map the current practices of management of patients by Oral Anti-cancer Drug (OAD) in inter-region. METHODS: Forty eight cancer centers received by e-mail in July and October 2016 a questionnaire concerning the management of OADs : from prescription by the specialist of oncology, to the intervention of the pharmacist (analysis and pharmaceutical consulting), to follow-up by nurse, as well as the financing of this activity and the feelings of the actors about this organizational set up. RESULTS: Fifty-seven professionals from 31 centers, including the most important ones, responded to the survey. As a result, half of the establishments carry out a pharmaceutical analysis for some or all of the OAD prescriptions and only 30% carry out a pharmaceutical consulting. The nurse consultation is, on the other hand, more largely implanted (74% of the centers) as well as the telephone follow-up (6%). More than 90% of professionals believe that the organizational set up could be improved and more secure by, at least, the stronger involvement of pharmacists, the development of tools for nurse (for monitoring, therapeutic education…) and by improving the city-hospital link. CONCLUSION: This survey shows the variability in the management of patients under OAD because of the lack of resources to ensure the fairness and sustainability of the organizational set up. The hospital/city link could still be optimized to secure patient care.


Subject(s)
Antineoplastic Agents/administration & dosage , Health Care Surveys/statistics & numerical data , Neoplasms/drug therapy , Administration, Oral , Cancer Care Facilities/statistics & numerical data , Continuity of Patient Care/statistics & numerical data , Drug Prescriptions , France , Humans , Nurse's Role , Organizational Objectives , Patient Satisfaction , Pharmacists , Practice Patterns, Nurses'/statistics & numerical data , Telephone
2.
Bull Cancer ; 100(3): 271-82, 2013 Mar.
Article in French | MEDLINE | ID: mdl-23518301

ABSTRACT

Optimizing the care management of patients is a major issue for our society. In Brittany-Pays-de-la-Loire (almost 10% of French population), an observatory of cancer has been created in 2003. Its main objective was the follow-up of expensive drugs. The knowledge of the use of these drugs in clinical practice has led to development of a thesaurus of good use. Thus, regular exchanges between clinicians have almost totally reduced not medically justified prescriptions by the thesaurus after and before administration to patient. The thesaurus has given away to national guidelines from 2007. For example, in these two regions, optimization of the use of gemcitabine and bevacizumab has allowed to save respectively 2.5 millions euros between 2005 and 2008 and 3 millions euros between 2009 and 2010 (breast cancer only). Optimizing the use of anticancer drugs has allowed a real health economy without any bad impact on patient management. Respecting medical ethics, the main objective remains to optimize health care. This highly participation of clinicians currently allows to reflect together on the relevance of the last chemotherapy.


Subject(s)
Antineoplastic Agents/economics , Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Quality Improvement/economics , Antibodies, Monoclonal, Humanized/economics , Antibodies, Monoclonal, Humanized/therapeutic use , Bevacizumab , Cost Savings/economics , Deoxycytidine/analogs & derivatives , Deoxycytidine/economics , Deoxycytidine/therapeutic use , Drug Costs , France , Humans , Quality Improvement/standards , Gemcitabine
SELECTION OF CITATIONS
SEARCH DETAIL
...